Abstract Acute and chronic alveolar or bronchial inflammation is thought to be central to the pathogenesis of many respiratory disorders. Cytokines and granulocyte macrophage colony-stimulating factors (GM-CSF) play an important role in chronic inflammation. Activator protein-1 (AP-1) the superfamily of transcription factors is involved in proliferation, differentiation, apoptosis, and transformation including inflammation. Understanding the function and regulation of proinflammatory factors involved in inflammation may provide the novel therapeutic strategies in the treatment of inflammatory diseases. Our aim of the present study is to investigate the pro-inflammatory cytokines and pattern of AP-1 factors expressed during activation of lung adenocarcinoma A549 cells by Phorbol-12-myristate-13-acetate (PMA) and to understand the antiinflammatory effect of apigenin. A549 cells were treated with and without PMA or apigenin, and the cell viability was assessed by MTT assay. Expressions of inflammatory mediators and different AP-1 factors were analyzed by semi-quantitative RT-PCR. IL-6 protein secreted was analyzed by ELISA, and expressions of IL-1b, c-Jun, and c-Fos proteins were analyzed by Western blotting. Activation of A549 cells by PMA, induced the expression of pro-inflammatory cytokine (IL-1b, IL-2, IL-6, IL-8, and TNF-a) mRNAs and secretion of IL-6 and the expression of specific AP-1 factors (c-Jun, c-Fos, and Fra-1). Treatment of cells with apigenin, significantly inhibited PMAstimulated mRNA expression of above pro-inflammatory cytokines, AP-1 factors, cyclooxygenase-2, and secretion of IL-6 protein. Results suggested that the AP-1 factors may be involved in inflammation and apigenin has antiinflammatory effect, which may be useful for therapeutic management of lung inflammatory diseases.
Introduction
Inflammation is a protective physiological response of the body to activate the immune system in response to a variety of stimuli, the infections, and tissue injury. However, chronic inflammatory response may induce various diseases such as sepsis, rheumatoid arthritis, and cancer [1, 2] . In response to bacterial infection or stimuli the pulmonary epithelial cells present at the mucosal surface are capable of secreting chemoattractants and pro-inflammatory cytokines, the important mediators in both lung defense and inflammation. Thus, the response of epithelial cells to inflammation acts as an early warning system to other local immune and inflammatory cells [3] . Cytokines (IL-6, TNFa, IL-8, and Granulocyte-macrophage colony-stimulating factor) are released in a coordinated network and among interleukins IL-6 acts as a pro-inflammatory cytokine and a potent mediator of inflammatory process [4] . In human respiratory disease, pulmonary epithelial cells are one of the major sources of prostaglandin E2 (PGE2) [5] . PGE2 are produced from arachidonic acid by inducible cyclooxygenase-2 (COX-2) [6, 7] . Induced expression of COX-2 and increased production of PGE2 have been implicated in many inflammatory diseases and pulmonary disorders [8] . Nitric oxide (NO) a free radical mediates many physiological processes [9] , and its production is controlled by inducible isoforms nitric oxide synthase (iNOS). Increased synthesis of NO in macrophages and lung cells also lead to many organ destruction and inflammatory autoimmune diseases.
The most studied transcription factors and most of the information exist during immune and inflammatory responses are nuclear factor-kappa-B (NF-kB) and activator protein-1 (AP-1) [10] . It is a well-known fact that NF-kB plays an important role in immune system [11] that regulate the expression of nearly all inflammatory mediators involved in inflammation [12] . AP-1 are involved in proliferation, differentiation, apoptosis, transformation, carcinogenesis, tumorigenesis, inflammation, and defense reactions [13] . AP-1 is a dimeric transcription factor comprising of proteins derived from two super families the Jun (c-Jun, JunB, and JunD) and the Fos (c-Fos, FosB, Fra-1, and Fra-2) proteins. Different combinational AP-1 dimers integrate numerous signaling pathways stimulated by great variety of extracellular cues and hence synthesis turnover of subunits of AP-1 transcription factors regulate many physiological or pathological status of an organism. Literature on AP-1 is very large, and the regulation and expression of different AP-1 subunits during differentiation, cell cycle, other pathophysiological processes, inflammation in macrophages and lungs are well defined [13, 14] . However, the expression pattern of different AP-1 factors in PMA-induced inflammation is less understood in lungs.
Long-term administration of non-steroidal anti-inflammatory drugs (NSAIDs) in the treatment of inflammatory diseases may result in severe adverse effects [15] . Hence, many natural products particularly flavonoids with an alleged anti-inflammatory activity have been used in the traditional medicine for treatment. Apigenin (4 0 ,5,7-trihydroxyflavone), is a flavone that is the aglycone found mainly in fruit, vegetables, nuts, and plant-derived beverages, shown to have non-toxic, non-mutagenic [16] , blocks the development of mouse skin tumors [17] , inhibits the proliferation of human breast-cancer cells [18] and is a potent antioxidant [19] , apigenin is known to inhibit high glucose levels and tumor necrosis factor-a (TNF-a)-induced adhesion molecule levels in human endothelial cells. Although large bodies of evidence exist in the use of apigenin in the treatment of inflammation, not much is known about its mechanism of anti-inflammatory action on AP-1 factors and pro-inflammatory cytokines in lungs. Hence in the present study, we aimed to demonstrate the expression pattern of different AP-1 factors on PMA-induced inflammation and the effect of apigenin on PMA-induced proinflammatory cytokines and AP-1 factors in human lung adenocarcinoma A549 cells.
Materials and methods

Materials
Lung adenocarcinoma alveolar type II A549 cells were purchased from NCCS (Pune, India), Phorbol 12-myristate 13-acetate (PMA), Apigenin, Griess reagent, oligos forward and reverse primers for different cytokines and AP-1 factors, cell cycle regulators, and apoptosis gene sequences were designed (Table 1 ) [20] and were purchased from Sigma-Aldrich (St Louis, USA). Fetal bovine serum (FBS), penicillin, streptomycin, glutamine, RPMI 1640 media, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), phenylmethanesulfonyl fluoride (PMSF), and trypan blue were purchased from Himedia (Mumbai, India). Superscript reverse transcriptases for qRT-PCR and IL-6 ELISA Kit were purchased from Invitrogen (CA, USA). Antibodies to c-Jun, c-Fos, and IL-1b were purchased from Neo-Biolab (MA, USA), and antirabbit antibody HRP conjugate was purchased from Imgenex India Pvt. Ltd. (Bhubaneswar, India). Taq DNA polymerase (1 U/ll) and Luminata Forte Western HRP substrate was procured from Merck-Millipore (Mumbai, India). Griess reagent was prepared in distilled water containing 1 % sulfanilamide in 5 % phosphoric acid and 0.1 % N-l-naphthylethylenediamine dihydrochloride. The cell lysis buffer was prepared in distilled water containing 50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1.0 % NP-40, and 100 lM PMSF.
Culturing of A549 cells A549 cells were grown in 75 cm 2 culture flask in RPMI 1640 media with 10 % FBS, 100 U/ml penicillin and 100 lg/ml streptomycin and 2 mM L-glutamine. Cells were cultured in a humidified atmosphere at 37°C by passing 5 % CO 2 in an incubator [21] . Flask containing 90-100 % confluent cells were sub-cultured in 96-well plate (3 9 10 3 cells/well) or in 6-well plate (5 9 10 5 cells/ well) for the treatment. (Whereever apigenin was used, the cells were preincubated 1 h either with two different concentrations of apigenin (20 or 40 lM), and then stimulated with PMA (10nM) for 2 and 24 h).
MTT assay for cell viability MTT assay for cell viability was carried out as per the protocol described earlier [22] . MTT is a pale yellow substrate taken up and reduced by active live cell 2 incubator. Blue formazan products formed inside the cells were dissolved in DMSO (100 ll), and absorbance was measured at 540 nm using spectrophotometer. The effect of PMA and apigenin on cell viability was calculated and represented graphically as % of viable cells compared to control.
Nitric oxide measurement NO produced by A549 cells was assayed by the measurement of nitrite, a stable NO oxidation product as described earlier [23] . Cells (5 9 10 5 cells/well) were plated in 6-well culture plate and incubated at 37°C for 24 h in a humidified 5 % CO 2 incubator. Later, the cells were treated with PMA (10nM) or apigenin (40 lM) alone or PMA with apigenin (20 or 40 lM) for 24 h. Spent culture medium aspirated from wells of culture plate (100 ll) was mixed with 100 ll of Griess reagent, and the absorbance of the mixture was measured in a microplate reader at 540 nm. Concentration of nitrite in lM was calculated using standard curve developed with known concentration of sodium nitrite.
RNA isolation and semi-quantitative RT-PCR analysis A549 cells (5 9 10
5 cells/well) were seeded into 6-well plate and incubated with or without PMA (10nM) or PMA and apigenin (20 lM or 40 lM) or apigenin alone (40 lM) for 2 and 24 h. Total RNA was isolated from each of the samples using ''Trizol reagent'' as per the instructions provided by the manufacturer. Reverse transcription of RNA and PCR analysis was carried out as per the protocol described earlier [24] . In brief, total RNA (2 lg) was reverse transcribed using Oligo (dT) primers and superscript reverse transcriptase. The cDNA was subjected to 30 cycles of PCR using different forward and reverse primers of inflammatory mediators or AP-1 factors or cell cycle regulators or apoptosis genes using appropriate annealing temperatures as indicated in Table 1 [20] in a gradient Eppendorf thermocycler. Amplified PCR products were analyzed on 1 % agarose gel using 1X TAE buffer. Relative mRNA levels were quantified using image analysis software (ImageJ). The expression of b-actin mRNA was used as a positive control and for normalization.
Enzyme-linked immunosorbent assay (ELISA) A549 cells (5 9 10 5 cells/well) were seeded into six-well plate and incubated with or without PMA (10nM) or PMA and apigenin (20 lM or 40 lM) or apigenin alone (40 lM) for 24 h. Cell-free culture supernatants (spent medium) were collected and stored at -80°C until further used. The amount of IL-6 protein present in spent medium was measured using Invitrogen ELISA kit. Standard (100 ll) or diluted control or treated samples (100 ll) were added into wells of ELISA 96-well plate. The Biotin conjugate (100 ll) was added, and incubated for 2 h at room temperature. The wells were washed four times with wash buffer, and 100 ll of Streptavidin-HRP solution was added, incubated further for 30 min at room temperature. The wells are washed thrice with wash buffer, 100 ll of Chromogen was added, incubated for 20 min at room temperature, and 100 ll of stop-solution was added to all the wells. Absorbance was measured at 450 nm using the PerkinElmer multimode plate reader (MA, USA). Concentrations of IL-6 in each samples were calculated using standard curve drawn with known concentration of recombinant cytokines and represented graphically.
Western blotting of IL-1b, c-Jun, and c-Fos
The total cell protein extracts of A549 cells from control and treated samples were prepared and analyzed by Western blotting as per the protocol described earlier [24] . The control and treated cells present in 6-well plate were washed thrice with PBS, and 0.2 ml of cold cell lysis buffer was added. Cells were scraped, and suspension was gently transferred to a pre-cooled Eppendorf tube, mixed gently by swirling on ice and centrifuged at 15,000 x g for 20 min at 4°C. Supernatant was used to determine protein concentration by Bradford's method [25] . The cell lysates containing equal amount of protein (40 lg) of different samples were separated on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and electrophoretically transferred on to PVDF membrane. The membrane was blocked with 5 % Carnation fat-free milk at room temperature for 1 h. Antibody (anti IL-1b or c-Jun or c-Fos) in blocking solution (1:500) was added and incubated for 1 h, washed and incubated with anti-rabbit antibody-HRP (1:500), and further incubated for 1 h at room temperature. Immunoreactive proteins were visualized using Luminata Forte Western HRP substrate and as per the specifications provided by the supplier in a Syngene Gel Documentation system (MD, USA). Immunoreactive bands were quantified using image analysis software (ImageJ). GAPDH was used as a positive control and for normalization.
Statistical analysis
The MTT assay, nitric oxide production, the images of semi-quantitative RT-PCR gels, ELISA, and Western blotting data were analyzed by one-way ANOVA followed by post-hoc tukey test. Values were considered statistically significant if *P \ 0.05, **P \ 0.005 compared to control and if # P \ 0.05 compared to PMA-treated sample.
Results
Effect of PMA and apigenin on A549 cells viability
The PMA used between 1-25nM concentration show no effect on the cell viability, while at 50 nM PMA show marginal decrease (5 %) in cell viability (Fig. 1a) . Similar results were also obtained by counting the number of viable cells by trypan blue dye exclusion method using Neubauer counting chamber (data not shown). To study the cytotoxic effect of apigenin, A549 cells were treated with or without different concentrations of apigenin (10-100 lM) for 24 h, and the cell viability was determined by MTT assay. Results show that the apigenin up to 60 lM concentration show no cytotoxic effect. However, compared to control a marginal decrease in cell viability at 80 and 100 lM concentrations of apigenin was observed (Fig. 1b) .
Effect of PMA and apigenin on Nitric Oxide production in A549 cells
The A549 cells were treated with LPS or PMA (10nM) or PMA and apigenin (20 or 40 lM) or apigenin (40 lM) alone for 24 h, and the concentration of nitrite in spent medium was determined using Griess reagent. The results
show that compared to control PMA alone has no effect on nitric oxide production, while PMA with apigenin at 20 and 40 lM concentration show marginal decrease in nitric oxide production. Apigenin alone also significantly inhibited NO production (18 %) compared to control (Fig. 2) . The positive control LPS found to induce significantly the nitric oxide production by more than 30 % compared to control (Fig. 2) .
Effect of PMA and apigenin on iNOS and COX-2 mRNA Expression
To assess the effect of PMA and apigenin on NO and PGE2 production in A549 cells, the mRNA levels of iNOS and COX-2 were analyzed by semi quantitative RT-PCR. In our study, PMA almost has no effect on iNOS expression, but induced the COX-2 mRNA expression by more than 3.3-fold compared to control (Fig. 3a) . The cells treated with PMA with apigenin decreased the PMA-induced mRNA levels of COX-2 in a dose-dependent manner. Cells treated with apigenin (40 lM) alone also show more than 30 % decrease in the expression of iNOS and 69 % decrease in COX-2 mRNA levels compared to control (Fig. 3a) . However, the positive control LPS induced the expression of iNOS by 34 % compared to control (Fig. 3b) .
Apigenin inhibits the PMA-induced mRNA expression of pro-inflammatory cytokines
Compared to control the treatment of A549 cells with PMA both at 2 and 24 h significantly induced the expression of all the pro-inflammatory cytokines (IL-1b, IL-6, IL-8, and TNF-a). However, IL-2 was found to be induced only at 24 h but not at 2 h. Among the pro-inflammatory cytokines studied, at 24 h maximum induction of more than 5.8-fold was observed for IL-6, 2.3-fold was observed for IL-2, and twofold was observed for TNF-a mRNA levels. At 2 h maximum induction of 2.7-fold was observed for IL-1b, 1.8-fold was observed for IL-8, and 1.7-fold was observed for TNF-a mRNA levels compared to control. The cells treated with apigenin (at 20 lM or 40 lM concentration) for 24 h significantly inhibited the PMA-induced expression of mRNA levels of all the above pro-inflammatory cytokines in a dose-dependent manner and almost reached to control levels (Fig. 4b) . At 2 h apigenin with 20 and 40 lM, significantly inhibited PMA induced the expression of mRNA levels of IL-1b and TNF-a while marginal decrease was observed for IL-6. However, apigenin at both the concentrations found to have no effect on IL-8 and IL-2 mRNA levels (Fig. 4a) . The cells treated with apigenin (40 lM) alone show no effect on IL-6, while significantly decreased the expression of IL-1b, IL-2 IL-8, and TNF-a mRNA levels compared to control (Fig. 4b) . Further, PMA and apigenin (20 and 40 lM) show no effect on anti-inflammatory IL-10 cytokine mRNA levels compared to control.
Apigenin inhibits the PMA-Induced synthesis and secretion of IL-6 cytokine .05 compared with PMA-stimulated values using one-way ANOVA followed by Post-hoc Tukey test. The bar graphs present below the respective figures are the densitometric analysis of mRNA levels protein into the medium. However, the cells treated with PMA and apigenin significantly decreased the PMAinduced IL-6 release in a dose-dependent manner. Cells treated with apigenin (40 lM) alone show marginal decrease in the secretion of IL-6 protein levels compared to control (Fig. 5) .
Apigenin inhibits the PMA-induced expression of mRNAs of c-Jun and c-Fos AP-1 factors A549 cells, except FosB, show the expression of mRNAs of Jun (c-Jun, JunB, and JunD) and Fos (Fra-1, Fra-2, and c-Fos) family members at different levels. Compared to control the cells treated with PMA induced the expression of c-Jun significantly by fourfold and fivefold, c-Fos by 2.6-fold and fourfold by 2 h and 24 h, respectively (Fig. 6a, b) . However, PMA marginally increased the expression of Jun-D and Fra-1 mRNA transcripts by 0.2-and 0.6-fold, respectively, at 24 h (Fig. 6b) . At 2 h PMA significantly increased the expression of Jun-B by 1.7-fold and marginally increased the expression of Fra-1 by 0.2-fold and Fra-2 by 0.27-fold (Fig. 6a) . The treatment of cells with apigenin at 20 or 40 lM significantly decreased the PMA-induced mRNA levels of c-Jun and c-Fos in a dose-dependent manner. All most no inhibition of PMA-induced Fra-1 mRNA levels at 20 and 40 lM concentration of apigenin was observed. Cells treated with apigenin (40 lM) alone showed marginal decrease in mRNA level of Jun-B and significant increase in mRNA transcripts of Fra-2 compared to control (Fig. 6b) . The results suggested that the c-Jun and c-Fos may be involved in inflammatory reaction and apigenin show anti-inflammatory activity in lung cells.
Apigenin inhibits PMA-Induced expression of IL-1b, c-Jun and c-Fos proteins in A549 cells
Our study also show that PMA induce significantly, the IL-1b protein by twofold and c-Jun proteins by more than 2.9-fold while marginal of 0.57-fold increase was observed for c-Fos. Apigenin at 20 lM and 40 lM concentrations show significant decrease in PMA-induced IL-1b protein, c-Jun, and c-Fos proteins in a dose-dependent manner (Fig. 7) .
PMA induces the cell cycle regulators
Cells treated with PMA induced the expression of mRNA levels of p53, CDK4, cyclin D1, and cyclin E1 transcripts at different levels. Results show that the PMA induces p53 mRNA by 2 and CDK4 mRNA by more than twofolds and marginal increase in 43 % of cyclin D1 mRNA levels (Fig. 8) . Apigenin treatment show the decreased PMA-induced expression of p53, cyclin D1 mRNA levels in a dose-dependent manner. However, apigenin treatment, either with PMA or alone show increased mRNA levels of CDK4 (Fig. 8) , while show decreased levels of cyclin E1 mRNAs suggested that the apigenin has varied effect on cell cycle regulators. .05 compared with PMA-stimulated values using oneway ANOVA followed by Post-hoc Tukey test. The bar graphs present below the respective figures are the densitometric analysis of mRNA levels the pro-apoptotic Bax mRNA expression compared to control (Fig. 9) . However, treatment of cells with apigenin (20 and 40 lM) decreased the PMA-induced Bcl-2 mRNA expression and increased the Bax expression to control mRNA levels. Apigenin alone found to have no effect on Bcl-2 and Bax gene expressions.
Discussion
Phytochemicals are important and promising group of compounds acts as a potential anti-inflammatory agents because of their low toxicity and apparent benefit in the treatment of acute and chronic diseases. Recently, the new approaches on the use of herbal products for the treatment of inflammatory diseases are being practiced in traditional medicine but without understanding their associated complications. Hence, our study focuses on the mechanism of action of bioflavonoid the apigenin, which is extensively used in alleviating the inflammatory diseases by inhibiting cytokines and TNF-a [26] . Apigenin is an anti-inflammatory molecule found in fruits and vegetables. Studies show that the apigenin inhibits the production of cytokines [27] and suppresses the LPS-induced NO production in macrophages [28] . Apigenin also found to inhibit the LPSinduced pro-inflammatory cytokine production in monocytes, mouse macrophages [29] and blocks the collagenase activity that is involved in rheumatoid arthritis. Apigenin exhibit an anti-inflammatory activity in a mechanism involving the action of heme oxygenese (HO-1) enzyme in hPDL cells. [30] . In the present study, we demonstrate the anti-inflammatory effect of apigenin on PMA-activated human pulmonary epithelial cells. Apigenin up to 60 lM concentration show no effect on the reduction in cell viability as measured by MTT assay and suggested that the flavonoid does not exhibit cytotoxic effect on lung cells.
The enzyme Nitric oxide synthase (NOS) is involved in the synthesis of nitric oxide (NO). Although, NO plays a [31] , its extensive activation may lead to various inflammatory diseases [32] . Hence, the decreased expression of inducible nitric oxide synthase (iNOS) is regarded as a therapeutic target for inflammation [33] . In our study A549 cells treated with PMA has no effect on NO production. However, apigenin alone or PMA with apigenin marginally inhibited NO production compared to control. The inhibitory activity of apigenin on NO production was also reflected in the suppression of iNOS mRNA levels. Another important major mediator of inflammation is COX-2 enzyme, which catalyzes the biosynthesis of prostaglandin-E 2 from arachidonic acid [34] . In A549 cells, COX-2 mRNA was expressed at low levels, but rapidly and transiently induced by PMA. Apigenin significantly decreases the PMA-induced mRNA levels of COX-2 in a dose-dependent manner which suggested the anti-inflammatory activity of flavonoid. Similarly in many tissues COX-2 is undetectable, but was found to be transiently induced by pro-inflammatory cytokines, growth factors, oncogenes, and PMA [35] .
In many tissues, the production of TNF-a and pro-inflammatory interleukins (IL-1b and IL-12) takes part in immune response to many inflammatory stimuli and overproduction of these mediators are detected in acute septic hemorrhagic shock [36] , and in chronic (rheumatoid arthritis, atherosclerosis) inflammatory disorders [37, 38] . Our results show that within 2 h of treatment of lung cells with PMA induced the expression of IL-1b, IL-6, IL-8, and TNF-a, while at 24 h IL-2 the pro-inflammatory cytokine was also induced. At 2 h of treatment of cells with apigenin significantly inhibited the PMA induced expression of mRNA levels of IL-1b and TNF-a while marginal decrease was observed for IL-6. However, apigenin at 24 h significantly decreased the expression of all the above proinflammatory cytokines studied in a dose-dependent manner. Treatment of A549 cells with PMA or PMA plus apigenin show no effect on anti-inflammatory IL-10 mRNA levels, suggested the specificity of PMA as well as apigenin action on pro-inflammatory cytokines. The mRNA level of IL-6 present in the cell was also reflected in the protein secretion. Treatment of cells with PMA shows significant induction in the secretion of IL-6 protein into the medium. However, the cells treated with PMA with apigenin significantly decreased the PMA-induced IL-6 release in a dose-dependent manner. Cells treated with apigenin (40 lM) alone show marginal decrease in the secretion of IL-6 protein levels compared to control. Western blotting result shows that treatment of cells with PMA significantly induced expression of IL-1b. However, PMA with apigenin significantly decreased the PMA-induced IL-1b expression. Cells treated with apigenin (40 lM) alone show decreased IL-1b protein expression compared to control. IL-8, acts as an important mediator of inflammation of CXC chemokine family recruits neutrophils into inflamed tissue [39] . Enhanced synthesis of IL-8 has been shown in the intestinal mucosa of patients suffering from inflammatory bowel disease (IBD) [37] . In our study, apigenin also suppress the PMA-induced IL-8 mRNA expression levels suggesting the anti-inflammatory effect of flavonoid in A549 cells.
In the present study, we also reported the expression pattern of all the AP-1 factors Although all the Jun and Fos proteins are expressed in A549 cells, only c-Jun, c-Fos, and Fra-1 were induced by PMA. In normal lobular and ducts, the epithelial cells show higher expression of FosB mRNA and protein, whereas in majority of carcinomas and MCF-7 cells less of FosB protein was expressed [40] , and this is in agreement with our study using A549 cells where little or no FosB mRNA expression was observed.
Western blotting also confirms the induced expression of c-Jun and c-Fos by PMA and apigenin decreased the expression by 24 h. Further, our study also show that PMA-induced p53 and cyclin D1 mRNA expression modulated to control levels by certain extent by increased concentration of apigenin. However, apigenin has stimulatory effect on CDK4 expression that needs to be investigated. Apigenin alone significantly decreased the cyclin E1 mRNA levels suggested that the flavonoids may have anti-proliferative and anti-cancerous effect on the lung cells challenged with the phorbol esters. Apigenin also show inhibitory effect on PMA-induced anti-apoptotic Bcl2 gene, confirms the therapeutic property of flavonoid [41] and probably has protective effect.
The anti-inflammatory effect of apigenin is probably based on the modulation of pro-inflammatory gene expression of cyclo-oxygenase, lipoxygenase, nitric oxide synthases, and several inflammatory cytokines and AP-1 factors mainly acting through NF-jB and MAPK signaling [42] . Because of their essential role in intracellular signaling network, MAPK pathways and the connected transcription factors are appropriate targets for pharmacological treatment of inflammatory disorders [43] . The flavonoids especially apigenin is required to be extensively investigated as possible regulatory molecule(s) in inflammatory processes.
Conclusion
Our study demonstrate that the treatment of apigenin inhibits and modulate the PMA-induced mRNA expression of cyclooxygenase-2 (COX-2) and pro-inflammatory cytokines IL-1b, IL-2, IL-6, IL-8, and tumor necrosis factor-a (TNF-a). Our study also confirms that apigenin decreased the expression of IL-1b protein and synthesis and secretion of IL-6. Apigenin also inhibited the PMA-induced expression of AP-1 factors (c-Jun and c-Fos) both at mRNA and protein levels. Hence, apigenin is a valuable source of new potential anti-inflammatory compound that may have therapeutic potential for the modulation and regulation of lung epithelial cell activation, and may provide safe and effective treatment options for variety of lung inflammation-mediated diseases.
